Millennium Pharmaceuticals Limited

Gitr, Inc.

Merck Sharp + Dohme Corp.

Other

The Brigham and Women's Hospital, Inc.

Children's Medical Center Corporation

Bristol-myers Squibb Compnay

Tolerx, Inc.

Tolerrx, Inc.

Paul D Ponath

Michael Rosenzweig

Jose F Ponte

Shixin Qin

Charles R Mackay

L Mary Smith

Walter Newman

Douglas J Ringler

David P Andrew

Grazyna Szymanska

Craig J Gerard

Norma P Gerard

Brian A Zabel

Theodore W Post

Irina Apostolou

Joe Ponte

Theresa O'Keefe

Mary M Bendig

S Tarran Jones

José W Saldanha

Lou Vaickus

Josephine M Cardarelli

Chin Pan

Bingliang Chen

Patricia Rao

Daniel E Lopes De Menezes

Brain A Zabel

Jose Ponte

José Saldanha

This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.

Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody

The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.

Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies

Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies

Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.

Anti-ILT5 antibodies and ILT5-binding antibody fragments

Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.

Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments

GITR antibodies and methods of inducing or enhancing an immune response

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Humanized anti-CCR2 antibodies and methods of use therefor

The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.

Combination therapies employing GITR binding molecules

Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies

The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof. Methods of using the binding molecules of the invention to detect human ILT3 or to modulate human ILT3 activity, either in vitro or in vivo, are also encompassed by the invention.

ILT3 binding molecules and uses therefor

Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to induce an immunostimulatory effect in a T cell when such a T cell is contacted with an antigen presenting cell (APC) that has been previously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to inhibit a response in a T cell (e.g., a pro-liferative response) when such a T cell is concomitantly contacted, or has previously been contacted, with an APC, which APC is simultaneously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.

Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies

Growing community of inventors

San Francisco, CA, United States of America

Paul D Ponath